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Abstract
Background: The identification of factors responsible for false negative (FN) rate at 18F- Fluorodeoxyglucose (FDG)
Positron Emission Tomography /Computed Tomography (PET/CT) in para-aortic (PA) lymph nodes in the presurgical
staging of patients with locally advanced cervical cancer (LACC) is challenging. The aim of this study was to
evaluate the impact of PET/CT technology.
Methods: A total of 240 consecutive patients with LACC (International Federation of Gynecology and Obstetrics,
FIGO, stage IB2-IVA) and negative Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT) and
negative 18F-FDG PET/CT in the PA region, undergoing laparoscopic PA lymphadenectomy before
chemoradiotherapy were included. The FN rate in patients studied with Time of flight (TOF) PET/CT (TOF PET) or
non-Time of flight PET/CT (no-TOF PET) technology was retrospectively compared.
Results: Patients presented with FIGO stage IB (n = 78), stage IIA-B (n = 134), stage III (n = 18) and stage IVa (n = 10),
squamous cell carcinoma (n = 191) and adenocarcinoma (n = 49). 141/240 patients were evaluated with no-TOF
PET/CT and 99/240 with TOF PET/CT. Twenty-two patients (9%) had PA nodal involvement at histological analysis
and considered PET/CT FN findings. The FN rate was 8.5% for no-TOF PET and 10% for TOF PET subgroup
respectively (p = 0.98). Ninety patients (38%) presented with pelvic node uptakes at PET/CT. The FN rate in the PA
region was 18% (16/90) and 4% (6/150) in patients with and without pelvic node involvement at PET/CT
respectively (19 vs 3% for no-TOF PET and 17 vs 5% for TOF PET subgroup).
Conclusions: In LACC, FN rate in PA lymph nodes detection is a clinical issue even for modern PET/CT, especially in
patients with pelvic uptake. Surgical lymphadenectomy should be performed in case of negative PET/CT at PA level
in these patients, while it could be discussed in the absence of pelvic uptake.
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Background
The therapeutic approach in locally advanced cervical
cancer (LACC) is a challenge and based on tumor vol-
ume, nodal metastasis, and clinical stage [1]. In LACC
(i.e. FIGO stage IB2 to IVA) chemoradiation in associ-
ation with pelvic External Beam Radiation Therapy
(EBRT) is recommended in case of metastatic pelvic but
negative Para-Aortic (PA) lymph nodes; in case of meta-
static PA lymph nodes, an extended radiation field to PA
region is applied [1, 2].
Therefore, imaging techniques with high diagnostic ac-
curacy are fundamental for disease staging. Diagnostic
imaging in cervical cancer includes abdomino-pelvic
Magnetic Resonance Imaging (MRI), Computed Tomog-
raphy (CT) scan and 18F-Fluorodeoxyglucose (FDG)
Positron Emission Tomography /Computed Tomog-
raphy (PET/CT) 18F-FDG PET/CT [3–6].
18F-FDG PET/CT may help to rule out loco-regional
lymph nodes and distant metastasis through a whole-
body examination. Indeed, recent guidelines recommend
PET/CT over CT in initial staging of LACC to detect
extra pelvic disease and for EBRT plan delineation [1].
However, in patients with LACC, high false negative rate
for PET/CT in detecting metastatic PA lymph nodes has
been reported in several published studies [7–11]. For
this reason, surgical staging is still considered in patients
with negative presurgical 18F-FDG PET/CT at PA level
[12]. During the last years, we assisted to a rapid devel-
opment of PET technology. In particular, the introduc-
tion of Time of Flight (TOF) technique using crystal
materials with relatively high time resolution should the-
oretically increase the sensitivity and consequently lesion
detectability [13–15].
The aim of this study is to determine the impact of
TOF PET/CT vs no-TOF PET/CT technology on false
negative rate in PA lymph node detection in the presur-
gical staging of patients with LACC.
Methods
Study design and patient enrolment
All consecutive patients with locally advanced cervical
cancer (LACC) according to FIGO classification (stage
IB2-IVA) treated between 2007 and 2015 at Gustave
Roussy (GR), with negative morphological imaging
(abdomino-pelvic MRI in most cases or CT scan and
pelvic MRI) and negative 18F-FDG PET/CT in the para-
aortic area (PA), undergoing laparoscopic PA lymphade-
nectomy before chemoradiotherapy were included. Pa-
tients with a poor prognosis according to histological
subtype or peritoneal carcinomatosis were excluded. In-
stitutional review board of Gustave Roussy approved the
study and waived the need to obtain informed consent.
The surgery included the removal of PA nodes from
the aortic bifurcation to the left renal vein. PA above
and below the inferior mesenteric artery, preaortic,
superficial intercavoaortic and precaval groups were re-
moved. Pelvic nodes were not resected because included
in the radiotherapy field.
All patients were treated with pelvic external beam
radiation therapy (45 to 50 Gy) associated to a concomi-
tant cisplatin-based chemotherapy protocol after
surgery. Patients with histologically proven PA node me-
tastasis after staging laparoscopic surgery were treated
with pelvic and extended to PA region EBRT (45 to 60
Gy) with concomitant cisplatin chemotherapy.
A total of 258 patients were initially evaluated. Eight-
een patients were excluded from analysis because of a
final IB1 staging with involved pelvic nodes (n = 9), small
cell carcinoma histology (n = 1), discovery of peritoneal
carcinomatosis during laparoscopy (n = 5), ovarian me-
tastasis (n = 1) and dubious findings for lymph node me-
tastases in the para-aortic region at PET/CT (n = 2)
(Fig. 1). In the end, a total of 240 patients were consid-
ered for the analysis and two subgroups of patients were
retrospectively identified according to the PET/CT tech-
nology used: patients studied with TOF PET/CT and pa-
tients studied with no-TOF PET/CT.
18F-FDG pet/CT
All the patients underwent a 18F-FDG PET/CT before
surgery. One hundred and eighteen patients underwent
18F-FDG PET/CT at Gustave Roussy and the remaining
122 in others different Nuclear Medicine Services in
France according to guidelines [16]. After 6 h of fasting,
patients performed images acquisition 60min after the
administration of a median activity of 254MBq of 18F-
FDG (range: 137–591MBq). Median glycaemia before
PET/CT was 4.6 mmol/L (range:0.74–10.4).
On the basis of constructor characteristics and recon-
struction algorithms, PET/CT scanners were divided
into two categories: TOF PET/CT (TOF PET) using 3D
coincidence algorithms for image reconstruction and in-
cluding TOF system (PET/CT Gemini-TF Philips, PET/
CT Biograph mCT20-mCT40 Siemens, PET/CT Discov-
ery 690 General Electric Healthcare, PET/CT Discovery
710 General Electric Healthcare) and no-TOF PET/CT
(no-TOF PET) with 2D-3D coincidence algorithms for
image reconstruction and not provided with TOF system
(PET/CT Biograph 6-Siemens, PET/CT Gemini GXL).
Statistical analyses
Patient characteristics were reported as relative/absolute
frequencies for categorical covariates and as median
(range) for continuous ones. Their potential differences,
when stratified as TOF-PET vs. no-TOF PET, were in-
ferred by the Fisher’s exact test for categorical variables
and the Mann-Whitney test for continuous ones. All re-
ported p-values were obtained by the two-sided exact
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method, at the conventional 5% significance level. Data




The median age was 45 years (21–68). Among 240 pa-
tients, 78/240 presented with stage IB, 134/240 with
stage IIA-B, 18/240 with stage III and 10/240 with stage
IVa of the disease respectively. One hundred ninety-one
patients (n = 191) had squamous cell carcinoma and 49
had adenocarcinoma. Patient Body Mass Index (BMI)
ranged from 14 to 43 Kg/m2 with a median of 23 Kg/
m2.
Before surgery, 18F-FDG PET showed uptake in pelvic
lymph nodes in 90/240 (38%) patients. The uptake was
unilateral in 57/90 (63%) patients, located in the right
(45%) and in the left region (51%) respectively (3.5%
Fig. 1 Consolidated standards of reporting Trials (CONSORT) DIAGRAM of the study
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Fig. 2 This is a case (a) of a patient with stage IIB cervical cancer (b blu arrow) studied with TOF PET/CT presenting pelvic pathological lymph
nodes (red arrow) located in right (b, c red arrow: 2 lymph nodes), in the left pelvic region (c red arrow: 1 lymph node) and in the common iliac
region. No significant uptake was present in the para-aortic region at. A single macrometastase in the para-aortic region was detected at
final histology
Table 1 Patient Population characteristics
Characteristics No of patients (N = 240) %
Age in years, median (range) 45 (21–68)






BMI in kg/m2, median (range) 23 (14–43)
Histologic subtype
Adenocarcinoma 49 20
Squamous cell carcinoma 191 80
Pelvic node uptake during PET imaging
No 150 62
Yes 90 38
Unilateral pelvic uptake 57 63
Bilateral pelvic uptake 33 37
Delay in days between PET-surgery, median (range) 15.5 (1–56)
No of para-aortic nodes removed, median (range) 15 (2–40)
No of patients with positive para-aortic nodes 22 9
Size of the biggest para-aortic nodes involved, mm
< 5 9 41
> 5 13 59
Abbreviations: FIGO International Federation of Gynecology and Obstetrics, BMI Body Mass Index, PET Positron Emission Tomography
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missing data). All patients with unilateral uptake pre-
sented with ≤2 positive lymph nodes at 18FDG PET/CT.
Pelvic uptake was bilateral in 33/90 (37%) of patients
(Fig. 2). Thirty patients presented with ≤2 positive lymph
nodes at 18FDG PET/CT by side, while the remaining 3
three patients presented with > 2 positive lymph nodes
(5 + 2 in 1 case, 2 + 3 in 1 case and 1 + 3 in 1 case in the
left and right region respectively). In the remaining 150/
240 (62%) there was no uptake in the pelvic region. In
regard to surgical laparoscopy techniques, 235 patients
underwent a retroperitoneal approach and five a trans-
peritoneal approach. One patient had conversion to
laparotomy. The mean delay between 18F-FDG PET/CT
and surgery was 15.5 days (range: 1–56). The median
number of removed PA lymph nodes per patient was 15
(range: 2–40). Twenty-two patients (9%) had para-aortic
nodal involvement at histological analysis considered as
FN PET findings with a median of 2 metastatic lymph
nodes per-patient (range: 1–8). Twenty-one patients had
squamous carcinoma and 1/22 had a clear cell adenocar-
cinoma subtype. In 13/22 (59%) the size of the biggest
PA involved node was > 5 mm while in the remaining 9/
22 (41%) the biggest size was ≤5 mm. Among the 22 pa-
tients with PA metastases, 16 presented pelvic 18F-FDG
uptake at PET/CT while the remaining 6 patients did
not. The FN rate in the PA region was 18% (16/90) and
4% (6/150) in patients with and without pelvic lymph
node uptake respectively. The FN rate was 16% (9/57)
and 21% (7/33) in patients with unilateral and bilateral
pelvic uptake respectively. Patient population character-
istics are summarized in Table 1.
TOF vs no-TOF PET/CT analysis
In relation to PET tomograph technology, 141/240 pa-
tients were evaluated with no-TOF PET/CT (73 at GR
and 68 in other centers) and 99/240 with TOF PET/CT
(45 at GR and the remaining 54 in other centers). Pa-
tient population characteristics of the two groups are
summarized in Table 2. Patients studied with TOF PET
were slightly older than no-TOF PET group (median age
48 vs 45 years; p = 0.009). The majority of patients were
classified as stage IIb, 73/141 (51.8%) compared to 48/99
Table 2 Patient Population characteristics according to the two groups (no-TOF PET and TOF PET technology)
Characteristics no-TOF (N = 141) TOF (N = 99) p-value
Age in years, median (range) 45 (21–68) 48 (22–65) 0.009
Tumor stage (FIGO classification)
IB2 50 (35.5%) 28 (28.3%)
IIa 5 (3.5%) 8 (8.1%)
IIb 73 (51.8%) 48 (48.5%) 0.36
III 8 (5.7%) 10 (10.1%)
IVa 5 (3.5%) 5 (5%)
BMI in kg/m2, median (range) 23 (14–42) 23 (16–35) 0.68
Histologic subtype
Adenocarcinoma 31 (22%) 18 (19%) 0.62
Squamous cell carcinoma 110 (78%) 81 (81%)
Median size primary tumor 48 mm (20–100) 45.5 mm (10–85) 0.32
Median SUVmax primary tumor 9.8 (3–43) 14.6 (5.6–35) < 0.001
Pelvic node uptake during PET imaging
No 93 (66%) 57 (58%)
Yes 48 (34%) 42 (42%) 0.5
Unilateral pelvic uptake 32 25
Bilateral pelvic uptake 16 17 0.83
Delay in days between PET-surgery, median (range) 15 (1–56) 17 (2–56) 0.22
No of para-aortic nodes removed, median (range) 15 (2–39) 16 (3–40) 0.25
No of patients with positive para-aortic nodes 12 (8.5%) 10 (10%) 0.98
Size of the biggest para-aortic nodes involved, mm
< 5 5 4
> 5 7 6 0.48
Abbreviations: TOF Time of Flight, FIGO International Federation of Gynecology and Obstetrics, BMI Body Mass Index, SUV Standardized Uptake Value, PET Positron
Emission Tomography
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(48.5%) in no-TOF and TOF PET group respectively
(p = 0.36). Before surgery, 18F-FDG PET showed uptake
in pelvic lymph nodes in 48/141 (34%) and 42/99 (42%)
patients evaluated with no-TOF and TOF PET/CT scan
respectively (p = 0.50). The median number of PA lymph
nodes removed was 15 (range: 2–39) and 16 (range: 3–
40) in the group of patients evaluated with no-TOF and
TOF PET/CT (p = 0.25) respectively. Amongst the first
group, 12/141 (8.5%) presented with metastatic PA
lymph nodes at histology compared to 10/99 (10%) in
the second group (p = 0.98). The maximum size of meta-
static PA lymph nodes was > 5 mm in 7/12 (58.3%) and
in 6/10 (60%) patients and ≤ 5 mm in 5/12 (41.7%) and
4/10 (40%) respectively in patients evaluated with no-
TOF and TOF PET/CT (p = 0.48). The FN rate was 19%
(9/48) and 17% (7/42) in patients with pelvic uptake and
3% (3/93) and 5% (3/57) in patients without pelvic up-
take in the no-TOF and TOF PET group. FN rate was
16% (5/32) and 16% (4/25) in cases of unilateral pelvic
uptake vs 25% (4/16) and 18% (3/17) in cases of bilateral
uptake in the no-TOF and TOF PET group (Table 3).
Discussion
PA lymph node metastases occur in 10–25% of patients
with LACC and are correlated with pelvic, common iliac
nodes involvement and larger primary tumor size [17,
18]. The detection of metastatic PA lymph nodes is a
fundamental step to define the correct therapeutic ap-
proach in LACC and to improve patient outcome [19–
22]. False negative rates for 18F-FDG PET and PET/CT
in PA areas have been reported in several studies ran-
ging from 5 to 17% [7, 11].
The identification of factors responsible for false nega-
tive PET/CT findings in PA region in LACC is challen-
ging. In the first studies on this topic, false negative rate
was mainly related to lymph node size < 5 mm consid-
ered beyond the machine resolution. In the study by
Roh et al. including patients with stages IA to IVA PET
sensitivity was 38% increasing to 52% in case of lymph
nodes > 5 mm and 65% in the case of lymph nodes > 10
mm [7].
The use of hybrid machines such as PET/CT has
greatly improved the accuracy of the technique allowing
a better localisation and characterisation of abdominal
FDG uptakes [23]. However, results among the studies
are variable and even in more recent studies false nega-
tive rate of 18F-FDG PET/CT remains high up to 22%, in
particular in early-stage disease [24–27]. The retrospect-
ive study by Leblanc et al. including 125 patients with
cervical cancer in stage IB2 –IIA with negative pre-
operative CT scans or MRI, FDG PET or PET/CT
showed a sensitivity of 33% in PA lymph nodes detection
with false negative rate of 67% [10]. A recent metanalysis
including 29 studies focused on 18F-FDG PET alone and
PET/CT reported a pooled sensitivity of 0.72 in detect-
ing both pelvic and PA lymph nodes, 0.83 in case of lo-
cally advanced disease and 0.41 in early-stage disease [6].
Another recent recent metanalysis from Yu et al. includ-
ing 14 studies evaluated specifically the diagnostic per-
formance of PET/CT for the detection of PA lymph
nodes [28]. The authors reported a pooled sensitivity
and a pooled specificity of 0.71 (95% CI: 0.54–0.83) and
0.97 (95% CI: 0.93–0.98) respectively and a pooled posi-
tive likelihood ratio (PLR) and negative likelihood ratio
NLR (NLR) of 21.53 and 0.30, respectively. The authors
concluded that 18F-FDG PET is an important imaging
method for the detection of PA lymph nodes but under-
line the limitations of the included studies, mostly retro-
spective and with low sample size. The ACRIN6671 trial
reported a sensitivity for 18F-FDG PET with contrast en-
hanced CT of 0.83 in the detection of pelvic lymph
nodes decreasing to 0.50 for PA lymph nodes [29].
In a previous multicentric prospective study evaluating
237 patients in the same setting, our group demon-
strated 18F-FDG PET/CT false negative rate of 12% and
the results supported the conclusion that PA lymph
node dissection should be performed in LACC in case of
negative 18F-FDG PET/CT in PA region for a proper pa-
tient staging [11].
The impact of PET device has never been taken into
account in order to evaluate and to compare accuracy in
this scenario. The aim of this study was to evaluate the
impact of PET/CT technology on false negative rate in
PA lymph node detection in LACC staging. In the last
decades there have been multiple advances in PET tech-
nology with improvement in cancer imaging [30]. The
Table 3 False negative rate of 18F-FDG PET/CT in para-aortic region according to pelvic uptake
Pelvic node uptake All patients (N = 22) no-TOF (N = 12) TOF (N = 10)
NO 4% (6/150) 3% (3/93) 5% (3/57)
YES 18% (16/90) 19% (9/48) 17% (7/42)
-unilateral 16% (9/57) 16% (5/32) 16% (4/25)
-bilateral 21% (7/33) 25% (4/16) 18% (3/17)
Abbreviations: TOF Time of Flight, 18F-FDG 18F- Fluorodeoxyglucose (FDG), PET/CT Positron Emission Tomography /Computed Tomography
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introduction of Time of Flight (TOF) technique using
crystal materials with relatively high time resolution
should increase the sensitivity and (consequently) lesion
detectability especially in overweight patients [31, 32].
This technology is useful in clinical practice, allowing
shorter examinations, reduction of the radiation dose to
the patient, successful scanning of overweight patients,
clearer characterisation of low uptake areas and
visualization of smaller lesions [31, 32].
Our data show that the false negative rate in PA lymph
node detection in patients evaluated by PET/CT scan
without TOF system integration compared to PET/CT
with TOF integration is comparable (8.5 vs 10%; p =
0.98). These findings suggest that even if the sensitivity
or lesion detectability is supposed to be higher in mod-
ern PET/CT scanner the limitation of the technique to
assess PA lymph node is still a clinical issue in this spe-
cific clinical setting. The resolution of the PET/CT tech-
nology with TOF is considered between 4 and 6mm [13,
31, 32]. Considering lesion size, in our study 59% of the
metastatic lymph nodes detected at histology presented
with a diameter > 5 mm with a similar distribution in the
two groups. In our opinion, the size cannot be consid-
ered the only cause of the false negative rates of 18F-
FDG PET/CT. Some studies suggest that 18F-FDG up-
take can be influenced by tumoral histotype in primary
and metastatic lesions, with higher 18F-FDG uptake in
squamous cell compared to non-squamous cell tumors.
In the study of Lin et al. nodal metastasis was less likely
to be detected by 18F-FDG-PET in patients with early-
stage adenocarcinoma compared to squamous carcin-
oma [33]. Nevertheless, in our study almost 80% of the
patients and 21/22 patients with false negative 18F FDG
PET/CT presented with squamous cell carcinoma. The
para-aortic lymph nodes are close to the urinary tract
and 18F-FDG physiological urinary elimination can hide
small 18F-FDG avid lesions. In this case, the use of
hybrid imaging such as PET/MRI and contrast en-
hanced diagnostic CT coupled with PET might better
differentiate between pathological and physiological
uptake, but well-designed trials are warranted to con-
firm this assumption [34]. Patient BMI should be also
taken into account because in overweight patients the
quality of images can be affected and the detection
rate reduced, but the BMI in the two groups of our
study was similar.
Finally, patients with pelvic pathological nodes metas-
tases, compared to patients without pathological pelvic
nodes, have a higher risk to develop PA metastases [17,
18]. In our study the percentage of pelvic positive lymph
nodes in TOF PET compared to no-TOF PET group
(42% vs 34%) was not statistically different (p = 0.5). FN
rate in PA region was higher in case of pelvic uptake at
18F-FDG PET/CT, especially when bilateral, compared
to negative pelvic uptake cases. These data are con-
firmed in both no-TOF and TOF PET groups with FN
rate of 19% vs 17 and 3% vs 5% respectively according to
pelvic vs no pelvic uptake status.
A very recent retrospective study (ONCO-GF) re-
ported a PET/CT sensitivity in identifying PA lymph
nodes metastases of 23.5%. Among 151 patients with
negative PA lymph node at PET/CT, 26 (17,2%) had
histological proven metastases including 21 with macro-
scopic lesions and the percentage increased considering
patients with positive pelvic uptake (18,1%) confirming
our observation. The authors conclude that para-aortic
surgical staging contributes significantly to individualise
the radiation treatment plan especially in patients with
positive pelvic uptake [35]. FRANCOGYN study includ-
ing 647 patients with LACC treated by concurrent
chemoradiation therapy (CRT) and no evidence of para-
aortic metastasis on pre-operative imaging work-up,
confirmed in multivariate model analysis surgical staging
as an independent prognostic factor for Disease Free
Survival [36]. On the other hand, a retrospective study
from Mayo Clinic registry including 148 patients did not
find differences comparing surgical versus radiological
staging (mainly based on CT, MRI and PET
combination) in 5-year PFS (HR 1.11, 95% CI 0.54–2.30,
p = 0.77) and 5-year OS (HR 1.02, 95% CI 0.46–2.29,
p = 0.96). The presence of PA lymph nodes metastasis
significantly predicted unfavourable PFS (HR 2.76, 95%
CI 1.23–6.18, p = 0.01) and OS (HR 3.46, 95% CI 1.40–
8.55 [37]. More consistent data will be forthcoming in
large trial of surgical vs radiological staging. A prospect-
ive study, including 600 patients with stage IB2- IVA
cervical cancer, is ongoing in order to evaluate the im-
pact on survival of standard chemoradiotherapy treat-
ment based only on 18F-FDG PET/CT staging compared
to an adapted treatment based on PA lymph node dis-
section staging [38]. However, considering our results
and previous published data, surgical lymph node dissec-
tion could be discussed in patients without involved pel-
vic lymph nodes on 18F-FDG PET/CT, considering the
very low false negative rate in this case. On the other
hand, in case of 18F-FDG PET/CT uptake in the pelvic
region, in particular if bilateral, the risk of FN findings
in PA lymph node is higher and surgical dissection could
be preferred.
Our study presents several limitations, in particular
the retrospective nature, the heterogeneity of the PET/
CT scanners employed and the lack of a standardized
protocol for images acquisition. Furthermore, for
strength conclusions on the impact of TOF technique a
direct comparison of images derived from the same pa-
tient with and without TOF reconstruction method
should be performed through a proper trial. On the
other hand, the impact of PET/CT device has been
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tested in a real clinical setting, in a wide sample size
population with histological confirmation, and in com-
parable patient populations. At this moment the increas-
ing availability of Digital PET scanner will probably
change the scenario and a direct comparison among dif-
ferent reconstruction methods will be the next step to
evaluate the impact of technological development in this
clinical setting. Finally, patients with positive PA at 18F-
FDG PET/CT have not been included in the study and
the analysis of true or false positive findings in the PA
region has not been performed because a reliable con-
firmation by histology would not have been available be-
ing the patient directly sent to extended EBRT protocol.
Conclusions
The FN rate in PA lymph nodes detection in LACC is
high, independently from PET/CT technology. Surgical
staging should be preferred in case of negative pre-
surgical imaging in the PA region, in particular in case
of 18F-FDG PET/CT abnormal uptakes in pelvic lymph
nodes. However, the FN rate in PA lymph nodes detec-
tion decreases dramatically in case of negative PET/CT
in pelvic region and surgical staging could be discussed
in this case. Prospective trials are mandatory to validate
this approach.
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